CGM Integration vs Closed-Loop Injection Pen Systems

Reviewed November 6, 2026 · For B2B procurement and development teams

Key parameters to define

• Integration level and exact claim
• CGM source, interface and latency
• Completeness of dose-event capture
• Therapy settings and decision owner
• Stale, missing and conflicting data behavior
• Manual confirmation versus automatic actuation
• System-level evidence and regulatory role

Four integration levels to distinguish

At the first level, an app simply displays glucose and injection records in one timeline. The second level adds pattern summaries or adherence insights. The third level uses glucose and therapy settings to calculate or recommend information for a user or clinician. The fourth level automatically changes and actuates delivery without the same manual decision step. These levels should never be collapsed into one phrase such as “CGM-connected dosing.” A system can integrate CGM data while remaining a manual multiple-daily-injection workflow. Even when a dose calculator is present, the prescribed settings, data delay, active-drug assumptions and user confirmation remain essential. Product pages and RFQs should state the exact level, supported sensors, transfer latency, responsible decision maker and whether the pen itself has any direct glucose-sensing capability.

Data timing and completeness define the risk

CGM data can be delayed, unavailable, out of range or routed through a cloud account rather than directly from the sensor. Injection data can also be incomplete if another pen, syringe or manual entry is used. A calculation or pattern analysis that combines these streams must define time synchronization, stale-data limits, missing-event handling, units, patient-specific settings and how conflicting sources are resolved. The interface should make gaps and delays visible instead of presenting a continuous-looking graph that implies complete information. Test cases should cover loss of connectivity, incorrect account linkage, phone replacement, daylight-saving or time-zone changes, duplicate dose records and multiple therapy devices. The stronger the decision-support claim, the stronger the requirements for data provenance and failure-state communication. Write acceptance criteria before testing so observations remain traceable to an approved requirement rather than being interpreted only after the result.

Write the claim before selecting the architecture

Begin with one sentence describing what the system will do, for whom, using which data and who takes the final action. Then map the components and regulated responsibilities needed to support that sentence. A visualization-only integration may rely on approved interfaces and clear data-source labeling. A dose recommendation adds software logic, therapy parameters, verification, human factors and clinical evidence. Automated control adds further safety, actuation, alarm, cybersecurity and system-level requirements. A pen supplier should not promise “closed loop” based on Bluetooth hardware alone. HYTANBIO can screen the device platform and integration assumptions, while the responsible product sponsor must define and substantiate the medical, software and market claims. Record the output, approval owner and change triggers in the project file so procurement, engineering, quality and regulatory teams use the same baseline.

Related technical paths

Connected Pen Data Guide · AI vs Smart Injection Pens · Smart Pen Platforms

Sources and verification

Use the primary sources below to verify the current requirement and its scope. Requirements can change by device, role, market and version; this guide was reviewed on September 21, 2026.

• Medtronic — InPen compatibility and integrations
• Medtronic — InPen system user guide
• FDA — Digital Health guidance collection

Questions buyers also ask